drug

LY03004

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Luye Pharma Group Ltd.
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
NCT02186769Phase 1Completed
Bioavailability of LY03004 and Risperdal® Consta®
NCT02091388Phase 1Completed
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
NCT02055287Phase 1Completed

KOLs & investigators

1
Simon Li

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Luye Pharma Group Ltd.
company
trial
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
PHASE1
trial
Bioavailability of LY03004 and Risperdal® Consta®
PHASE1
trial
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Simon Li
KOL score —
person